%0 Journal Article
%A Haussmann, Jan
%A Budach, Wilfried
%A Nestle-Krämling, Carolin
%A Wollandt, Sylvia
%A Jazmati, Danny
%A Tamaskovics, Bálint
%A Corradini, Stefanie
%A Bölke, Edwin
%A Haussmann, Alexander
%A Audretsch, Werner
%A Matuschek, Christiane
%T Factors influencing pathological complete response and tumor regression in neoadjuvant radiotherapy and chemotherapy for high-risk breast cancer.
%J Radiation oncology
%V 19
%N 1
%@ 1748-717X
%C London
%I BioMed Central
%M DKFZ-2024-01568
%P 99
%D 2024
%X Pathological complete response (pCR) is a well-established prognostic factor in breast cancer treated with neoadjuvant systemic therapy (naST). The determining factors of pCR are known to be intrinsic subtype, proliferation index, grading, clinical tumor and nodal stage as well as type of systemic therapy. The addition of neoadjuvant radiotherapy (naRT) to this paradigm might improve response, freedom from disease, toxicity and cosmetic outcome compared to adjuvant radiotherapy. The factors for pCR and primary tumor regression when neoadjuvant radiation therapy is added to chemotherapy have not been thoroughly described.We performed a retrospective analysis of 341 patients (cT1-cT4/cN0-N+) treated with naRT and naST between 1990 and 2003. Patients underwent naRT to the breast and mostly to the supra-/infraclavicular lymph nodes combined with an electron or brachytherapy boost. NaST was given either sequentially or simultaneously to naRT using different regimens. We used the univariate and multivariate regression analysis to estimate the effect of different subgroups and treatment modalities on pCR (ypT0/Tis and ypN0) as well as complete primary tumor response (ypT0/Tis; bpCR) in our cohort. Receiver operating characteristic (ROC) analysis was performed to evaluate the interval between radiotherapy (RT) and resection (Rx) as well as radiotherapy dose.Out of 341 patients, pCR and pbCR were achieved in 31
%K Humans
%K Female
%K Breast Neoplasms: pathology
%K Breast Neoplasms: radiotherapy
%K Breast Neoplasms: therapy
%K Neoadjuvant Therapy
%K Middle Aged
%K Retrospective Studies
%K Adult
%K Aged
%K Radiotherapy, Adjuvant
%K Prognosis
%K Antineoplastic Combined Chemotherapy Protocols: therapeutic use
%K Treatment Outcome
%K ROC Curve
%K Breast cancer (Other)
%K Breast response (Other)
%K Neoadjuvant chemotherapy (Other)
%K Neoadjuvant radiotherapy (Other)
%K pCR (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39085866
%2 pmc:PMC11293047
%R 10.1186/s13014-024-02450-5
%U https://inrepo02.dkfz.de/record/291985